Lanxess (LXS) Q4 2025 (Media) earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 (Media) earnings summary
1 May, 2026Executive summary
Revenue declined 10.9% year-over-year to EUR 5.673 billion in 2025, with EBITDA pre exceptionals down 16.9% to EUR 510 million, mainly due to weak demand, portfolio changes, and adverse currency effects.
Completed divestment of plastics businesses, including Urethane Systems, reducing dependency on plastics and improving sustainability profile.
Transformation towards Consumer Protection and specialty chemicals continued, with Consumer Protection EBITDA stable at EUR 290 million and a margin of 15.4%.
Announced EUR 100 million in permanent cost reductions and 550 job cuts, mainly in Germany, to be completed by 2028.
Net financial debt reduced by 15.0% to EUR 2.023 billion, with robust financing and no capital increase planned.
Financial highlights
Group sales declined 10.9% and EBITDA fell 16.9% year-over-year.
Net income dropped to EUR -577 million from EUR -177 million year-over-year.
Consumer Protection segment EBITDA remained stable at EUR 290 million, margin up to 15.4%.
Specialty Additives revenue declined 6.9%, EBITDA down 11.5% to EUR 201 million, margin at 9.8%.
Advanced Intermediates revenue dropped 8.4%, EBITDA down 39.0% to EUR 128 million, margin at 7.7%.
Outlook and guidance
EBITDA pre exceptionals for 2026 expected between EUR 450 and 550 million, with no contribution from divested urethanes business and no exceptional items as in 2025.
Recovery anticipated in the second half of 2026, supported by potential government stimulus.
No substantial improvement in plant utilization expected in 2026, though some pickup seen since March.
Ongoing cost savings and production network optimization expected to support gradual EBITDA growth.
Latest events from Lanxess
- 2026 EBITDA guidance is €450–550 million, with recovery expected in H2 2026.LXS
Q4 202519 Mar 2026 - Earnings rose, costs fell, and sustainability advanced amid global uncertainty and strategic refocus.LXS
AGM 20253 Feb 2026 - Q2 2024 EBITDA pre exceptionals surged 69% year-over-year despite lower sales.LXS
Q2 20241 Feb 2026 - EBITDA pre exceptionals jumped 45% and net income returned to profit in Q3 2024.LXS
Q3 202416 Jan 2026 - EBITDA rose 20% in 2024 as cost savings and portfolio focus drove profitability gains.LXS
Q4 202426 Dec 2025 - Q2 sales and EBITDA fell on weak demand, but net debt dropped after Urethane divestment.LXS
Q2 202523 Nov 2025 - EBITDA pre up 32% to €133m; guidance held as Urethane sale supports debt reduction.LXS
Q1 202517 Nov 2025 - EBITDA pre exceptionals rose 32% in Q1 2025, with guidance confirmed at €600–650 million.LXS
Q1 2025(Media)17 Nov 2025 - Sales and EBITDA fell sharply in Q3 2025, with cost cuts and divestments improving leverage.LXS
Q3 20256 Nov 2025